SDTM001
/ Cytocraft Biopharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 01, 2025
SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection
(clinicaltrials.gov)
- P1 | N=22 | Recruiting | Sponsor: Cytocraft Biopharmaceutical Co., Ltd.
IO biomarker • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1
1 to 1
Of
1
Go to page
1